Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.60 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867511 | 0.85 | GABRA1 (0.60) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL5118750 | 0.82 | ADORA3 (0.44) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL6867476 | 0.81 | GABRA1 (0.57) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 | |
| SCHEMBL6868305 | 0.79 | GABRA1 (0.66) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 | |
| Amidate SCHEMBL22502728 | 0.77 | GABRA1 (0.97) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 | |
| Amidate SCHEMBL39485 | 0.75 | GABRA1 (1.00) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 | |
| Amidate SCHEMBL1817757 | 0.75 | GABRA1 (1.00) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 | |
| S-Etomidate SCHEMBL39486 | 0.75 | GABRA1 (1.00) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 | |
| Etomidate SCHEMBL39487 | 0.75 | GABRA1 (1.00) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 | |
| Amidate SCHEMBL28276 | 0.75 | GABRA1 (0.93) | GABRA1GABRB2CYP1A2CYP3A4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | WARNER-LAMBERT COMPANY LLC | 2008-10-16 | — | — | US | disclosed |
| EP-1749004-B1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1749004-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105801-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | TYMS, DPYD, TYMP | GABRA1 3240/4885GABRB2 3942/4885CYP1A2 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.